Boston Landing Lands its First Two Life-Sciences Tenants

80 Guest Street

BOSTON–NB Development Group, LLC, the development company behind the mixed-use Boston Landing development project along the I-90 Mass Pike in Brighton, MA announced that they have inked leases with their first two Life-Science companies.

Roche Diagnostics Operations, Inc. will take occupancy of its space during the first half of 2018.  Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

Roche and Proteostasis are life-science lab space at 80 Guest Street, a 246,405 square feet building comprised of office, life-science lab, and retail space. Both tenants have leased approximately 29,000 square feet each. With the latest two leases the building is now 40 percent leased.

Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. On this transaction, Roche was represented by the Cushman & Wakefield team of David Klein, Kevin Hanna and Connor Barnes.  The NB Development Group Team of Jim Halliday, Bob Graham, Erin Harvey, and Keith Craig represented themselves.

80 Guest Street

Proteostasis Therapeutics, Inc. will also take occupancy of its space during the first half of 2018.  Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery of groundbreaking therapies to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

Proteostasis Therapeutics is developing investigational drugs targeting the cystic fibrosis transmembrane conductance regulator protein, and is currently conducting clinical trials with CFTR amplifier PTI-428, corrector PTI-801 and potentiator PTI-808.  Bob Richards of Transwestern represented Proteostasis Therapeutics, while NB Development Group was represented by Transwestern’s Steve Purpura and Perry Beal working with the NB Development Group team of Jim Halliday, Bob Graham, Erin Harvey, and Keith Craig.

“We are excited to continue the transformation of Boston Landing with the addition of both Roche Diagnostics and Proteostasis Therapeutics as both are engaged in important and innovative discoveries centered around health & wellness,” said Jim Halliday, Managing Director of NB Development Group.  “The work and values of both these companies align well with enhancing the innovation and health & wellness spirit already entrenched with the presence of New Balance, the Boston Bruins and the Boston Celtics, as well as the investment made by John Hancock in the residential project at Boston Landing.  With the growth in life-science activity within the Cambridge-Boston market, at Boston Landing we look forward to continuing our inroads in attracting other innovative life-sciences and other R&D tech minded industries to the Boston Landing campus.”

Located minutes from Downtown, Boston Landing is a smart growth project consisting of approximately 1.76 million sf.  The development will include diverse property types, including three new laboratory/office buildings, an NHL regulation hockey arena for the Boston Bruins, the newly announced practice facility for the Boston Celtics, a hotel, a world class track & field / multi-sport & event center, a residential apartment building, a commuter rail station on the Framingham/Worcester line and amenity-driven retail. The development is currently home to New Balance Athletics, Inc., Harvard Business School Publishing, Global Atlantic and WGBH amongst other reputable entities.